The treatment offers hope to thousands of patients who do not respond to existing medications, and has shown promise in treating other neurological disorders.
The U.S. Foodand DrugAdministration late Thursday approved ... treatment in decades,” Tiffany Farchione, director of FDA’s division of psychiatry, said in a statement.